June 3, 2026
View Full Paper2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Key Points
- The guidelines aim to improve the diagnosis and treatment of hypertrophic cardiomyopathy in affected patients.
- Review of existing literature on hypertrophic cardiomyopathy diagnosis and treatment
- Development of consensus recommendations by expert panels
- Focus on risk assessment and management strategies
- Updated diagnostic criteria enhance early detection of hypertrophic cardiomyopathy
- New treatment protocols improve patient outcomes and management
- Risk stratification tools aid in identifying high-risk patients for adverse events
Abstract
No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.
Expert Takes4 quotes
1/4
“Shared decision-making, a dialogue between patients and their care team that includes full disclosure of all testing and treatment options, discussion of the risks and benefits of those options and, importantly, engagement of the patient to express their own goals, is particularly relevant in the management of conditions such as hypertrophic cardiomyopathy. This updated guideline places emphasis on including the patient in the decision-making process rather than simply providing dogmatic lists of do's and don'ts.”
Steve R. Ommen, Professor of medicine, Mayo Clinic College of MedicineMayo Clinicauto_pipelineView source